Live Breaking News & Updates on Modeling The Association Of Selected Medications

Stay updated with breaking news from Modeling the association of selected medications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AD/PD™ 2021, Including Lecanemab (BAN2401) Data

Wednesday, March 10
Lecture Time: 12:45 - 13:00
Live Discussion: 17:00 - 17:30
Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE/ENGAGE,
Phase 3 Studies of Aducanumab in Patients with Early Alzheimer s Disease
Session: Aβ Targeting Therapies in AD 2
Saturday, March 13
Lecture Time: 12:45 - 13:00
Live Discussion: 17:30 - 18:00
Evaluation of Aducanumab Efficacy in Early Alzheimer s Disease.
Session: Aβ Targeting Therapies in AD 2
Saturday, March 13
Lecture Time: 13:00 - 13:15
Live Discussion: 17:30 - 18:00
Evaluation of Aducanumab Safety in Early Alzheimer s Disease.
This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval. ....

National Institutes Of Health , United States , New Jersey , North Carolina , Libby Holman , Philip Scheltens , Donaldr Miller , John Hardy , Jeffrey Cummings , Ivan Cheung , Michelle Gee , Kazuto Yamashita Sysmex , National Institute On , Biogen Inc , Modeling The Association Of Selected Medications , Health Administration , European Union , Health System Preparedness For Alzheimer Disease Treatment , Eisai Inc , International Conference On Alzheimer , Eisai Co Ltd , Neurology Business Group , Us Veteran Affairs , Eisai Missionad Program , Alzheimer Clinical Trial Consortium , International Conference ,

Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AD/PD™ 2021, Including Lecanemab (BAN2401) Data

Eisai Alzheimer s Disease Pipeline Research to be Presented at Virtual AD/PD™ 2021, Including Lecanemab (BAN2401) Data
- Oral presentations and posters highlighting Eisai s investigational novel therapies and immunoassay system being studied for Alzheimer s disease and its clinical symptoms
- Preliminary analyses evaluating brain amyloid beta reduction with lecanemab to be featured in oral presentation
- Virtual symposium: The Science Behind the Aβ Pathway in Alzheimer s Disease
News provided by
Share this article
Share this article
WOODCLIFF LAKE, N.J., March 5, 2021 /PRNewswire/ Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of data and information from the company s robust Alzheimer s disease (AD) pipeline, including lecanemab (BAN2401). Jointly developed by Eisai and Biogen Inc., lecanemab is an investigational humanized monoclonal antibody that binds to neutralize and eliminate soluble, tox ....

National Institutes Of Health , United States , New Jersey , North Carolina , Libby Holman , Philip Scheltens , Donaldr Miller , John Hardy , Jeffrey Cummings , Ivan Cheung , Michelle Gee , Kazuto Yamashita Sysmex , National Institute On , Biogen Inc , Modeling The Association Of Selected Medications , Health Administration , European Union , Health System Preparedness For Alzheimer Disease Treatment , Eisai Inc , International Conference On Alzheimer , Eisai Co Ltd , Neurology Business Group , Us Veteran Affairs , Eisai Missionad Program , Alzheimer Clinical Trial Consortium , International Conference ,